CTRI/2021/03/032072已完成3 期
A Prospective, Single center, single arm study to Evaluate Efficacy and safety of Ayurvedic Kadha in health and immunity related parameters in mild COVID-19 patients. - Kadha
MARC Laboratories Ltd0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age > 18 years
- •2. Written Informed consent is documented
- •3. COVID-19 positive clinical symptoms and (subsequently) confirmed by the current recommended confirmatory test (RT PCR).
- •4. Can take oral medicines.
- •5. Mild-moderate grade of the disease.
排除标准
- •1. Known sensitivity to any of the ingredients
- •2. Bleeding haemorrhoids
- •3. Serious stages of the illnesses
- •4. ICU admitted patients
- •5. Pre-existing GI symptoms like nausea or vomiting
研究者
相似试验
尚未招募
4 期
Clinical study to asses the CT angiography results following the use of the MeRes100 Sirolimus-Eluting Bioresorbable Vascular Scaffold System in patients with coronary artery disease.CTRI/2024/04/066128Dr Keyur Parikh
进行中（未招募）
3 期
Efficacy and safety of Sirolimus granules twice daily administration in patients with intractuable vascular malformationsIntractable vascular malformationsVascular disordersD054079JPRN-jRCTs031200055Mochizuki Shinji11
招募中
2 期
Study for assessing the effect of blood level guided adjustment of posconazole doses (an oral drug to prevent fungal infections) in preventing fungal infections in blood cancer patientsCTRI/2017/06/008810Tata Memorial Hospital90
撤回
3 期
A Prospective, Multi-Center, Single Arm Study of the Conor Cobalt Chromium Reservoir Based Stent (Nevo) with Sirolimus Elution in Native Coronary Artery Lesions (CP-07 protocol)atherosclerosisNL-OMON32462Conor Medsystems, LLC (maakt deel uit van Johnson & Johnson); contact persoon Emily Hergenreter40
已完成
Unknown
OFT-G1-301 StudyCongenital heart diseaseJPRN-jRCT1080224691TEIJIN LIMITED / TEIJIN PHARMA LIMITED30